Inactief instrument

Andere talen Fresh Start Private Management Inc Other OTC

Aandelen

US35804J1025

slotkoers Other OTC Andere beurzen
- ^USD	-

15/05	BioCorRx Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
03/04	BioCorRx Inc. Kondigt ontslag van de Raad van Bestuur aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioCorRx Reports Business Update for the First Quarter of 2024	16/05
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
BioCorRx Inc. Announces Board Resignations	03/04
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	03/04
BioCorRx Reports Business Update for 2023	02/04
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	28/02
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	08/02
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	08/02
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	09/01
BioCorRx Inc. Announces President Changes	05/01
BioCorRx : Material Agreement - Form 8-K	15/12
BioCorRx Inc. announced that it has received $0.2 million in funding	08/12
BioCorRx Reports Business Update for the Third Quarter of 2023	14/11
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
BioCorRx Inc. announced that it has received $0.2 million in funding	10/11
Biocorrx Inc. Announces Management Changes	02/11
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15-08-23
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15-08-23
BioCorRx Reports Business Update for the Second Quarter of 2023	14-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fresh Start Private Management Inc Other OTC

Aandelen

US35804J1025

Andere talen

Filters